Press Releases Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:42 2026-04-17 EDT			5-day change	1st Jan Change
118.82 ^CHF	+1.19%		-2.41%	+8.41%

04-15	Tango Therapeutics, Inc. Announces Leadership Appointments	CI
04-15	Novartis CEO joins Anthropic board of directors

Press Releases

04-09	Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030	GL
04-09	Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030	GL
03-30	Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%	AQ
03-30	Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation	AQ
03-29	Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%	GL
03-27	Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation	GL
03-23	Novartis agrees to acquire a pan-mutant-selective PI3Ka inhibitor, strengthening its breast cancer pipeline	AQ
03-23	Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026	GL
03-20	Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline	GL
03-13	Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa	GL
03-06	Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting	GL
03-02	Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy	AQ
02-27	Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy	GL
02-27	Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)	GL
02-25	Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients	GL
02-25	Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients	GL
02-24	New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer	GL
02-23	Novartis presents Rhapsido data at AAAAI, showing potential beyond chronic spontaneous urticaria	AQ
02-23	Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)	GL
02-18	Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)	GL
02-16	Novartis : Q4 2025 impact and sustainability update	PU
02-13	Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy	GL
02-09	Novartis : ESG Data Summary 2025	PU
02-09	Novartis : Update	PU
02-09	Novartis : SASB index	PU